Working… Menu

Influence of Tocolytical Medications on Hemodynamics (Central and Peripheral) and Vascular Function in a Pilot Study to Determine the Design of the Final Study and the Final Study Itself

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00679705
Recruitment Status : Completed
First Posted : May 19, 2008
Last Update Posted : April 20, 2009
Information provided by:
University Hospital, Ghent

Brief Summary:

This trial will consist of two parts:

A pilot study in a three-way cross over trial to determine the highest well tolerated dose of Ritodrine (Pre-Par®), the impact of Atosiban (Tractocile®) on the hemodynamics and hence the design of the final study.

The final study is planned as a three-way crossover trial to investigate and compare the cardiovascular effects of Ritodrine, Atosiban and placebo to relate those effects to the pharmacokinetics of Ritodrine and Atosiban (PK/PD modelling).

Condition or disease Intervention/treatment Phase
Healthy Drug: Ritodrine Drug: Atosiban Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Pilot Study: A Dose-Response Finding Study of Ritodrine (Pre-Par®) to Find the Highest Well Tolerated Dose in Young, Healthy, Female Volunteers. To Find the Size-Order of the Hemodynamical Effects of Ritodrine (PrePar®) and Atosiban (Tractocile®) to Determine the Relevance of a PK/PD-Modelling in the Final Study. Final Study: Investigating the Influence of Tocolytical Medications: Ritodrine (PrePar®) and Atosiban (Tractocile®) at the Clinical Dose on the Hemodynamics and Arterial Function in Healthy Female Volunteers, Compared to Placebo During Continuous Intravenous Infusion.
Study Start Date : May 2008
Actual Primary Completion Date : November 2008
Actual Study Completion Date : November 2008

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1
Ritodrine (Pre-Par)
Drug: Ritodrine
Ritodrine (Pre-Par), maximum 400 µg/minute, IV

Experimental: 2
Atosiban (Tractocile)
Drug: Atosiban
Atosiban (Tractocile), maximum 300 µg/minute, IV

Placebo Comparator: 3
Drug: Placebo
Glucose 5%, IV

Primary Outcome Measures :
  1. Hemodynamical effects of Ritodrine and Atosiban in comparison of those of placebo. [ Time Frame: 240 minutes ]

Secondary Outcome Measures :
  1. Effect of the specific dosing levels of the medications on the level of arterial stiffness [ Time Frame: 240 minutes ]
  2. Effect of the specific dosing levels of the medications on the effects of the peripheral pulse wave reflections on the central, systolic blood pressure [ Time Frame: 240 minutes ]
  3. Effect of the specific dosing levels of the medications on the distensibility of the blood vessel wall [ Time Frame: 240 minutes ]
  4. Effect of the specific dosing levels of the medications on the cardiac output and total peripheral resistance [ Time Frame: 240 minutes ]
  5. Effect of the specific dosing levels of the medications on peripheral brachial, systolic and diastolic blood pressure [ Time Frame: 240 minutes ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age between 20 and 40 years old;
  • In good health, especially no cardiovascular diseases, obstructive lung diseases, chronic kidney diseases or diabetes mellitus.
  • Using a proper anticonception method (orally, subcutaneously);
  • A negative pregnancy test.

Exclusion Criteria:

  • Intolerance of Ritodrine;
  • On chronic medication, except oral and subcutaneous contraception
  • History or present presentation of cardiac arrythmias;
  • Risk of being pregnant or less than 6 months postpartum;
  • Giving breastfeeding;
  • Previous uteral surgery;
  • Using an intra-uteral device (IUD);
  • A severe addiction: nicotine (> 10 cigarettes/day), alcohol (> 3 units/day), caffeine (> 5 units/day) or any extralegally drugs.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00679705

Layout table for location information
University Hospital Ghent
Ghent, Belgium, 9000
Sponsors and Collaborators
University Hospital, Ghent
Layout table for investigator information
Principal Investigator: Luc Van Bortel, MD, PhD University Hospital, Ghent
Additional Information:
Layout table for additonal information
Responsible Party: Luc Van Bortel, MD, PhD, University Hospital Ghent Identifier: NCT00679705    
Other Study ID Numbers: 2008/110
First Posted: May 19, 2008    Key Record Dates
Last Update Posted: April 20, 2009
Last Verified: April 2009
Keywords provided by University Hospital, Ghent:
Hemodynamics and arterial function of healthy females
Additional relevant MeSH terms:
Layout table for MeSH terms
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Tocolytic Agents
Reproductive Control Agents
Autonomic Agents
Peripheral Nervous System Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action